Select Page

Acetylcholine Receptor-Ab (ARAb) Blocking RIA

Radio immunoassay for the quantitative determination of blocking autoantibodies against the acetylcholine receptor.

SKU: RE21031 Category:


Myasthenia gravis (MG) is an acquired disorder of neuromuscular transmission associated with abnormal muscle weakness and fatigue on exertion.

This muscle weakness increases with muscle activity, eventually reaching a state of pseudoparalysis. After muscle relaxation, the motility is restored. Muscles that are required for body posture, including facial and neck muscles as well as ocular muscles and muscles needed for speaking and swallowing, are most affected. Clinical symptoms may be restricted to one muscle group, like the eye muscles (ocular MG), or become generalized (generalized MG). Myasthenia gravis can occur from early childhood to old age and its prevalence is about 5 per 100,000. In women, the disease usually presents between the ages of 20 to 40, whereas in men the age of presentation tends to be between 40 and 60 years. The incidence of MG is 40 to 60 new cases per million people, per year. Autoantibodies directed against acetylcholine receptors along the postsynaptic membrane are responsible for the muscle weakness and fatigue in MG. Three functionally different types of antibodies against acetylcholine receptors are detectable in patients with MG: receptor binding, blocking and modulating antibodies. Related to the blocking antibodies there is a significant correlation between the degree of acetylcholine receptor blockade and generalization of muscle weakness. Therefore, measurement of blocking acetylcholine receptor autoantibodies is of additional value in differential diagnosis of MG.

  • Product Code:


  • Brand:

    TECAN (IBL International GmbH)

  • Assay Type:

    ELISA (Enzyme Immunoassay)

  • Sample Types(s):
  • Area of Interest:
  • Regulatory Status:

    Research Use Only